Document is current

Article History

Received: 19 March 2025

Accepted: 27 June 2025

First Online: 6 August 2025

Declarations

:

: KE: Travel Expenses: AstraZeneca, Daiichi Sankyo, MSD Teaching: Astellas Pharma, Daiichi Sankyo IS: Research support (paid to institution) from Amgen, AstraZeneca, Bayer, BioInvent, BioNTech, Boehringer Ingelheim, Bristol-Myers Squibb, CDR Life, Dragonfly Therapeutics, Eli Lilly, Genentech, Genmab, Incyte, Monta Bioscience, MSD, Novartis, Orion, Pfizer, Puma Biotechnology, Repare Therapeutics, Roche. Honoraria: AstraZeneca. Support for travel, accommodation, and congress registration: AstraZeneca and Incyte. KSR: Research support (paid to institution) from Amgen, AstraZeneca, Bayer, BioInvent, BioNTech, Black Diamond Therapeutics, Bristol Myers Squibb, CDR Life, Dragonfly Therapeutics, Eli Lilly, Genentech, Genmab, Incyte, Merck, Monta Bioscience, Merk Sharp & Dohme, Navire, Novartis MH: Research support (paid to institution) from Amgen, AstraZeneca, Bayer, BioInvent, BioNTech, Black Diamond Therapeutics, Bridge Bio Oncology, Bristol Myers Squibb, CDR Life, Dragonfly Therapeutics, Eli Lilly, Genentech, Genmab, Incyte, Kinnate Biopharma, Merck, Monta Bioscience, Merk Sharp & Dohme, Navire, Novartis, Pfizer, Repare Therapeutics and Servier Oncology. Travel expenses: Repare Therapeutics MR: Consulting or Advisory Role: AstraZeneca, MSD. Research Funding: AstraZeneca (Inst), Pfizer, Servier, and Repare; consulting or advisory roles for AbbVie, Bayer, Roche, and Novartis. ES-R has received research grants (paid to institution) from Roche, Sanofi and Takeda; honoraria for lectures (paid to institution) from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, and Takeda; and payment for participation in Advisory Board (paid to institution) from Roche and Takeda. MMS has served on an advisory board for PUMA Biotechnologies and received an unrestricted research grant from PUMA Biotechnologies. Others authors have no COI to declare.